Neurocrine Biosciences
NBIX
466 hedge funds and large institutions have $10B invested in Neurocrine Biosciences in 2022 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 162 increasing their positions, 160 reducing their positions, and 44 closing their positions.
82% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 44
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
28% more call options, than puts
Call options by funds: $35.1M | Put options by funds: $27.4M
18% more capital invested
Capital invested by funds: $8.45B → $10B (+$1.55B)
7% more funds holding
Funds holding: 437 → 466 (+29)
5.82% more ownership
Funds ownership: 93.82% → 99.65% (+5.8%)
1% more repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 160
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$471M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
+$80.4M |
| 3 |
Amundi
Paris,
France
|
+$76.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$64.5M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$43.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$253M |
| 2 |
Holocene Advisors
New York
|
-$67.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$64.9M |
| 4 |
JP Morgan Chase
New York
|
-$63.6M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$61.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MFT
501
Moisand Fitzgerald Tamayo
Orlando,
Florida
| – | -$3K | -32 | Closed |
|
|
AA
502
Ancora Advisors
Cleveland,
Ohio
| – | -$2K | -21 | Closed |
|
|
PMFA
503
Plante Moran Financial Advisors
Southfield,
Michigan
| – | -$2K | -18 | Closed |
|
504
Jones Financial Companies
Des Peres,
Missouri
| – | -$1K | -13 | Closed |
|
|
SFG
505
Steward Financial Group
Colleyville,
Texas
| – | -$1K | -11 | Closed |
|
|
FMP
506
Financial Management Professionals
Austin,
Texas
| – | -$1.01K | -10 | -83% |
|
|
DI
507
Disciplined Investments
Tulsa,
Oklahoma
| – | +$203 | +2 | New |
|
|
SIC
508
SJS Investment Consulting
Sylvania,
Ohio
| – | +$406 | +4 | New |
|
NBIX Hedge Fund Activity: Q3 2022 in Review
466 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2022, worth a combined $10B — up 18% from $8.45B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new NBIX positions and 44 closed out — a net gain of 36 holders — while 162 added to existing stakes and 160 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $471M. The largest seller was T. Rowe Price Associates, cutting an estimated $253M.
- 466 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2022, up from 437 in Q2 2022.
- Funds reported $10B of Neurocrine Biosciences stock for Q3 2022, up 18% quarter-over-quarter.
- 80 funds opened new Neurocrine Biosciences positions in Q3 2022 and 44 closed out, a net change of +36 holders.
- The largest Neurocrine Biosciences buyer in Q3 2022 was Janus Henderson Group, an estimated $471M added.
- The largest Neurocrine Biosciences seller in Q3 2022 was T. Rowe Price Associates, an estimated $253M sold.
Based on aggregated 13F filings for Q3 2022.